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Histidine decarboxylase (HDC) is expressed by the
cells of melanoma, in which the histamine content
tends to be relatively high. This study shows that ele-
vated expression of HDC was found by western blot
analysis of primary and metastatic melanoma tissue
using a polyclonal HDC speci®c antibody. The speci-
®city of anti-HDC antibody was con®rmed by inhib-
ition of HDC translation (i.e., immunopositivity) in
melanoma cells by HDC-speci®c antisense oligonu-
cleotide. Moreover, the decrease in proliferation
caused by HDC antisense oligonucleotides indicates
considerable functional relevance of histamine syn-
thesis in melanoma growth and suggests a possible in
situ application of speci®c antisense oligonucleotides
for HDC in melanoma therapy. J Invest Dermatol
117:151±153, 2001
A
ccording to recent ideas, the production of growth
factors by melanoma cells may provide an escape from
exogenous mechanisms regulating the proliferation of
normal cells (Moretti et al, 1999). Histamine, one of
the biogenic amines with general physiologic im-
portance, occurs abundantly in tumor tissue, and high gene
expression of L-histidine decarboxylase (HDC) has been recently
described in melanoma tissue and cell lines (Haak-Frendscho et al,
2000). This study shows a high HDC expression in clinical samples
from 25 patients suffering from melanoma. Striking antiprolifera-
tive effect of HDC-speci®c antisense oligonucleotides (ASO)
demonstrated under in vitro conditions suggests a possible successful
alternative way for the local human therapy of melanoma.
MATERIALS AND METHODS
Patients and tissue samples Thirty-®ve human tissue samples were
studied. The tissue biopsies were removed by surgical excision from 28
patients. The samples were frozen at ±80°C for western blotting.
The sex and age distribution of 28 patients was as follows: 15 females
(between 28 and 86 y) and 13 males (from 34 to 81 y). The examined
samples were: three dysplastic naevi (two females, one male), 20
melanomas (melanoma at different Clark stages and Breslaw index; 12
females, eight males), ®ve metastatic melanoma lesions (cutaneous or
lymph node; three males, two females), and 10 samples from skin regions
surrounding the primary cutaneous melanoma (®ve males and ®ve
females).
Melanoma cell lines Primary melanomas: WM35 and WM983/B
(growing preferentially vertically and horizontally, respectively).
Metastatic lines: HT168 (metastatic xenograft, previously generated
subcutaneous in vivo passaging of A2058 cells in IS CBA/Ca mice) cell
line with low liver metastatic capacity, and M1/15 with high liver
metastatic capacity.
HDC western blotting and immunostaining Primary polyclonal
antibodies against human HDC protein were produced in chicken (IgY)
(Haak-Frendscho et al, 2000). Antibodies were prepared using the amino
acid sequence 318±325 (VKDKYKLQ) of the human HDC and used
after af®nity puri®cation. Speci®city of anti-HDC antibodies is
demonstrated in Fig 1, showing that absorbance with increasing amount
of immunizing fusion construct removes the 55 kDa (HDC) band.
The cells were lyzed and homogenized in a buffer containing 10 mM
Tris HCl pH 8.0, 1% Triton-X, 0.5 mM EGTA, 10 mg leupeptin per
ml, 5 mM NaF, 50 mM Na-othovanadate, 25 mM PMSF. Fifteen
micrograms lysate was loaded on the denaturing polyacrylamide gel (10%
running gel and 5% stacking gel, 110 V, 20 mA, 2 h). After blotting
(Hoefer instrument, Amersham Immobilon-P paper, Tris-HCl, glycine,
methanol buffer, 370 mA, 45 min), the membrane was gently shaken in
a blocking solution [5% low-fat milk powder in phosphate buffered
saline (Sigma, Budapest, Hungary) + 0.1% Tween 20] for 1 h at room
temperature. HDC band was revealed by subsequent treatment with
anti-HDC antibody (40 ng per ml for 1 h). HRPO-labeled antichicken
IgY secondary antibody (Promega, Madison, WI, 100 ng per ml) was
then used for 30 min and visualized with an ECL (Amersham, Bucks)
Western blotting kit. For immunohistochemistry of melanoma cell lines,
monolayers were ®xed in acetone (20°C, 10 min), then stained by
chicken anti-HDC antibody (10 mg per ml, overnight, 4°C). After three
washes with ice-cold PBS, FITC labeled rabbit antichicken IgY second-
ary antibody (0.5 mg per ml, 20°C, 3 h) was applied. Cell nuclei were
stained with 1.5 mg per ml propidium iodine (Sigma). After three washes,
the cells were examined with a confocal microscope (Bio-Rad,
Budapest, Hungary).
HDC-speci®c ASO ASO were selected based on the sequence data of
HDC cDNA (Accession NM_002112). Three HDC ASO ± HGT AGA
CGG TCA TGG ACH (cDNA nt. 71±87), HCT CGG GTT CCC
TCT ACH (cDNA nt.90±105), HHT ATA AAA CTT AGA GAC
(cDNA nt.1260±1275) ± were tried in previous optimization
experiments (not shown) and the one corresponding to the positions of
cDNA nt. 1260±1275 was used in the experiments.
Cell proliferation Melanoma cells (105 per ml) were incubated on 24-
well plates in the presence of HDC ASO (30 mg per ml) and 20 mg per
ml DNA uptake stimulating factor (DUSF; ToÂth et al, 1998) in the
medium. Nonsense oligonucleotide mixture and DUSF were used as
control. After 48 and 96 h, the cells were washed with PBS-EDTA
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(0.01 M) and counted. Uptake and catabolism of ASO in melanoma cells
and other cell lines had been controlled as in earlier experiments
(RadvaÂny et al, 2000). Brie¯y, 3H-labeled antisense oligonucleotides
were mixed with HDC-ASO in the presence of increasing amounts of
unlabeled ASO (both antisense and nonsense). After incubation and
washings, the uptake and stability of ASO were tested. These
experiments showed the speci®c inhibition of HDC antisense ASO by
``cold'' speci®c, but not by ``cold'' nonsense oligonucleotides. Moreover,
the stability of HDC ASO were con®rmed by the activity of tritiated
ASO decreasing by less than 2% over a further 72 h. All experiments
were performed in triplicates.
Statistical analysis was performed by Student t analysis and by one way
ANOVA.
RESULTS AND DISCUSSION
Table I shows the frequency of HDC protein in melanoma
biopsies. Strong expression of HDC in both primary and metastatic
Figure 2. Effect of HDC antisense
oligonucleotides on HDC immunopositivity
of human melanoma cells. (A, B) WM983/B,
(D, E) HT168/91 human melanoma cells in the
presence of mixture of nonsense oligonucleotides
(A, D) and HDC antisense oligonucleotide (B, E).
Scale bar: (A, B, D, F) 5 mM; (C, F) 10 mM.
Figure 1. Western immunoblotting of polyclonal anti-HDC
chicken antibody with a lysate from melanoma cell line WM35.
The af®nity puri®ed antibody had been absorbed with increasing
amounts of immunogenic fusion protein containing the speci®c
immunogenic peptide (VKDKYKLQ) sequence.
Table I. HDC immunopositivity (western immunoblot) of
tissue specimen from patients with primary melanoma,
metastatic tissues, and naevi and from normal skin samples
(for details see Materials and Methods)
Tissue specimen 0 + ve
Primary melanomaa 1 19
Metastasisb 0 5
Dysplastic nevic 1 2
Normal skind 8 2
aTwelve females, 8 males; b2 females, 3 males; c2 females, 1 male; d5 females, 5
males.
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melanoma and low frequency in naevi and normal skin with about
25±10-fold lower expression con®rms our earlier data (Haak-
Frendscho et al, 2000) concerning the presence of HDC mRNA
and protein in melanoma cell lines and tissues and their absence in
normal human melanocytes.
HDC-speci®c and nonsense 18-mer ASO were taken up by both
the primary (WM 983/B, WM 35) and the metastatic (HT168/91,
M1/15) human melanoma cell lines, as controlled by uptake of 3H-
labeled nucleotides (not shown).
Speci®c ASO completely abolished (Figs 2B, E) the immunos-
taining (i.e., translation) of HDC in WM983/B (A-C) and HT168/
91 (D-F), con®rming the speci®city of the anti-HDC antibody.
Mixture of nonsense 18-mer ASO (Figs 2A, D) had no effect on
HDC immunoreactivity.
As a functional consequence of the inhibition of HDC protein
synthesis, speci®c antisense oligonucleotide strongly (> 50%)
decreased the proliferation rate of both WM938/B and HT168/
91 human melanoma cell cultures by 48±96 h (Fig 3), whereas no
effects of the nonsense ASO were detected. Similar effects were
found with the other two melanoma cell lines WM35 and M1/15
(not shown).
Following the ®rst observation of the presence of histamine in
rapidly growing tissues (Kahlson et al, 1963), numerous experi-
ments in tumor-bearing animals have suggested that high HDC
activity is of fundamental importance for tumor development
(Cricco et al, 1994). Under various tumor conditions, endogenous
histamine may act as an autocrine growth factor, in¯uencing cell
proliferation via H2 histamine receptors (Burtin et al, 1988; Bolton
et al, 2000). A more indirect way of in¯uencing melanoma growth
by locally produced histamine is by its suppression of the
production of IFN-g by surrounding immune cells (e.g., T
lymphocytes and natural killer cells; HorvaÂth et al, 1999), which
effectively impairs their antitumor activity and contributes to escape
of melanoma cells from immunosurveillance. Interestingly, IFN-g
in turn decreases HDC expression (Heninger et al, 2000). These
reciprocal effects re¯ect a highly complex regulatory network
acting in the close microenvironment of melanoma cells. Because
histamine in¯uences de novo angiogenesis locally, it acts as a further
form of tumor surveillance that is enhanced by locally produced
histamine (Rizzo and DeFouw, 1996).
Our data demonstrate that HDC-speci®c antisense oligonu-
cleotide substantially decreases the expression of HDC in
melanoma cell lines, with simultaneous inhibition of their
proliferation. These data are promising because recently increas-
ing attention has been drawn toward locally therapeutic
application of antisense oligonucleotides by Akhtar and
Agrawal (1997). An 18-mer phosphorothioated ASO comple-
mentary to bcl-2, administered at 5 mg per kg per d for 21 d to
severely compromised, immunode®cient (SCID) mice inoculated
with follicular lymphoma cells eliminated lymphoma cells in six
of six mice (Wagner, 1997). Moreover, the in vivo transduction
of prostate cancer cells with MMTV-antisense c-myc retro-
viruses reduced tumor growth by suppressing c-myc, resulting
in the downregulation of bcl-2 protein (Steiner et al, 1998). A
similar successful approach has been described in the course of
therapy for tumors of the central nervous system by Chung and
Chiocca (1998). Free access to genomic data and EST libraries
of melanoma cells provide a greater chance that not only
traditional antihistamines, such as H2 histamine antagonists
(Bolton et al, 2000), but also antisense oligonucleotides targeting
HDC translation, may also soon become candidates for a locally
applicable, in situ therapy for melanoma.
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Figure 3. The effect of an 18mer HDC-ASO on the proliferation
of WM938/B and HT168/91 human melanoma cells. (A) WM938/
B; (B) HT168/91. Control: open columns, nonsense oligonucleotide
mixture: stripped columns, HDC ASO: black columns. N = 4, mean
6 SEM is shown. *p < 0.01.
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